Ameris Bancorp (ABCB) · Oct 22, 2026 · Earnings
Beat — Diluted EPS $1.73 vs ~$1.71 consensus
Ameris Bancorp earnings narrowly beat EPS expectations as net interest income and deposits grew, though mortgage revenue fell and nonperforming assets worsened.
Ameris is a Southeast-focused regional bank pursuing disciplined organic growth through core deposits, commercial lending, mortgage, warehouse lending and premium finance; its strategy emphasizes low-cost funding and balance-sheet growth across expanding southeastern markets.
The quarter narrowly beat the earnings bar. Diluted EPS was $1.73 versus a published consensus near $1.71, making this a small beat rather than a major reset. The underlying result was cleaner than the headline comparison with the prior quarter: adjusted EPS also came in at $1.73, up 14% from $1.52 a year ago. (Financial Highlights, Table 1)
| Metric | 3Q26 | Comparison | Filing source |
|---|---|---|---|
| Diluted EPS | $1.73 | $1.54 in 3Q25; ~$1.71 consensus | Financial Highlights, Table 1 |
| Adjusted diluted EPS | $1.73 | $1.52 in 3Q25; $1.60 in 2Q26 | Financial Highlights, Table 1 |
| Net interest income, tax-equivalent | $258.6M | +8.2% year over year | Net interest income discussion; Table 7 |
| Net interest margin | 3.87% | 3.80% in 3Q25; 3.88% in 2Q26 | Financial Highlights, Table 1 |
| Total deposits | $22.91B | +5.6% annualized in 3Q26 | Period End Balance Sheet, Table 3 |
| Loans | $22.35B | +3.1% annualized in 3Q26 | Loan Information, Table 5 |
| Adjusted efficiency ratio | 49.15% | 50.42% in 2Q26 | Adjusted Efficiency Ratio, Table 9B |
| Nonperforming assets / assets | 0.54% | 0.47% in 2Q26; 0.40% excluding GNMA loans | Asset Quality Information, Table 4 |
The core banking engine held up well. Tax-equivalent net interest income rose $5.2 million sequentially and $19.7 million year over year, while the margin stayed essentially flat sequentially and improved year over year. Deposits grew faster than loans, supporting the company’s funding position, but the mix was less favorable: interest-bearing deposits increased while noninterest-bearing deposits fell $87.8 million.
The beat was partly offset by weaker fee businesses. Noninterest income fell $9.4 million sequentially, driven by a $7.2 million decline in securities gains and a $3.3 million decline in mortgage banking income. Mortgage production and the open pipeline also contracted, so the quarter’s better EPS relied more heavily on spread income and cost control than on broad-based revenue growth.
Credit quality is the main complication. Net charge-offs improved slightly to 19 basis points, and the loan-loss allowance remained at 1.62% of loans, but nonperforming assets rose to 0.54% of assets, or 0.40% excluding government-guaranteed mortgages. That is still manageable in absolute terms, yet it moves the credit trend in the wrong direction for a bank with substantial commercial real estate exposure.
The new buyback authorization adds capital-return support, not a new earnings driver. The board authorized up to $200 million of repurchases through October 31, 2027, replenishing an existing program rather than introducing an unexpected strategic shift. It reinforces management’s confidence in capital levels, but the authorization is discretionary and does not commit the company to repurchase a specific amount.
Bottom line: Ameris delivered a narrow earnings beat with solid core spread income, deposit growth and efficiency, but weaker mortgage revenue and rising nonperforming assets keep this from being a clean acceleration story. The filing modestly advances the organic-growth narrative while leaving credit normalization as the key constraint to watch.
Q3 earnings call, October 23
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!